GlassScriptPhysician profile
William M Lewis
NPI 1265401350
$2,475.82
in general payments reported to CMS, 2019-2025
30 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $79.37 · 2021: $91.49 · 2022: $250 · 2023: $534 · 2024: $787 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.78 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $277.63 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $257.39 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $166.04 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $163.68 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.54 | 2023-2025 | Jardiance |
| Mylan Specialty L.P. | $137.21 | 2023-2024 | Yupelri |
| Abbott Laboratories | $136.87 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $88.70 | 2022-2025 | Evenity, Prolia |
| Pfizer INC. | $85.00 | 2022-2025 | |
| Exact Sciences Corporation | $81.36 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $65.79 | 2024-2025 | Injectafer |
| Dynavax Technologies Corporation | $60.66 | 2022-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $56.64 | 2023 | Inspire |
| Abbvie INC. | $42.82 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32.50 | 2019-2020 | |
| Boston Scientific Corporation | $32.38 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2024 | Gattex |
| Pulmonx Corporation | $28.07 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $28.04 | 2019-2020 | |
| Averitas Pharma INC. | $26.59 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $23.35 | 2022 | |
| Radius Health, INC. | $17.84 | 2023 | Tymlos |
| Recordati_rare_diseases_inc. | $17.27 | 2025 | Isturisa |
| Redhill Biopharma INC. | $17.23 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.70 | 2024 | Zoryve |
| Idorsia Pharmaceuticals US INC | $15.67 | 2024 | Quviviq |
| Althera Pharmaceuticals LLC | $15.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.68 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.